Advertisement
BBIO vs PMN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a StrongBuy and PMN is a Hold.
BBIO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for BBIO turned positive on October 01, 2026. Looking at past instances where BBIO's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BBIO's RSI Oscillator exited the oversold zone, 12 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BBIO as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
Following a +0.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBIO advanced for three days, in 246 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for BBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for BBIO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.295) is normal, around the industry mean (2.973). P/E Ratio (-19.135) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. BBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PMN's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for PMN moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 27 of the 31 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where PMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for PMN just turned positive on October 21, 2026. Looking at past instances where PMN's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.
Following a +5.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 158 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMN as a result. In 99 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
PMN moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.570) is normal, around the industry mean (2.973). P/E Ratio (-0.685) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BBIO | PMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 72 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 57 | 83 | |
P/E GROWTH RATING 1..100 | 24 | 12 | |
SEASONALITY SCORE 1..100 | 47 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BBIO's Valuation (7) in the null industry is significantly better than the same rating for PMN (91). This means that BBIO’s stock grew significantly faster than PMN’s over the last 12 months.
BBIO's Profit vs Risk Rating (72) in the null industry is in the same range as PMN (100). This means that BBIO’s stock grew similarly to PMN’s over the last 12 months.
PMN's SMR Rating (99) in the null industry is in the same range as BBIO (100). This means that PMN’s stock grew similarly to BBIO’s over the last 12 months.
BBIO's Price Growth Rating (57) in the null industry is in the same range as PMN (83). This means that BBIO’s stock grew similarly to PMN’s over the last 12 months.
PMN's P/E Growth Rating (12) in the null industry is in the same range as BBIO (24). This means that PMN’s stock grew similarly to BBIO’s over the last 12 months.
| BBIO | PMN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 84% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 82% | 14 days ago 84% |
| Declines ODDS (%) | 15 days ago 81% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 78% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBIO’s FA Score shows that 2 FA rating(s) are green while PMN’s FA Score has 1 green FA rating(s).
- BBIO’s FA Score: 2 green, 3 red.
- PMN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBIO’s TA Score shows that 5 TA indicator(s) are bullish while PMN’s TA Score has 5 bullish TA indicator(s).
- BBIO’s TA Score: 5 bullish, 4 bearish.
- PMN’s TA Score: 5 bullish, 5 bearish.
Price Growth
BBIO (@Biotechnology) experienced а +1.47% price change this week, while PMN (@Biotechnology) price change was -0.57% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
BBIO is expected to report earnings on Nov 04, 2026.
PMN is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with DYN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | +0.56% | ||
| DYN - BBIO | 47% Loosely correlated | -1.87% | ||
| AXON - BBIO | 44% Loosely correlated | +2.98% | ||
| ARRY - BBIO | 43% Loosely correlated | -3.23% | ||
| PMN - BBIO | 43% Loosely correlated | -5.26% | ||
| KURA - BBIO | 41% Loosely correlated | -0.20% | ||
More | ||||